The plasmacytoid dendritic cell paradox in cancer: impaired type I interferon responses in a nucleic acid–rich tumor microenvironment - Top-Institutions - MDSpire

The plasmacytoid dendritic cell paradox in cancer: impaired type I interferon responses in a nucleic acid–rich tumor microenvironment

By
Aliki Vasilakou
Séverine Loizon
Maxime Dubois
Paôline Laurent
Vanja Sisirak
Dorothée Duluc
July 2, 2026
0 min

Frontiers In Immunology

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

The University of Texas MD Anderson Cancer Center

Houston, Texas
Key Differentiators
- Oncology
#2

Memorial Sloan Kettering Cancer Center

New York, New York
Key Differentiators
- Oncology
#3

Karolinska Institutet

Stockholm, Sweden
Key Differentiators
- Oncology
#4

University of Copenhagen

Copenhagen, Denmark
Key Differentiators
- Oncology
#5

Academic Medical Center Amsterdam

Amsterdam, Netherlands
Key Differentiators
- Oncology

Original Source(s)

Frontiers In Immunology

The plasmacytoid dendritic cell paradox in cancer: impaired type I interferon responses in a nucleic acid–rich tumor microenvironment

by Aliki Vasilakou, Séverine Loizon, Maxime Dubois, Paôline Laurent, Vanja Sisirak, Dorothée Duluc
July 2, 2026

Related Content

Frontiers In Digital Health

From voice biomarkers to telemedicine screening: developing and evaluating a voice-based AI model for laryngeal lesion detection using the Bridge2AI-Voice dataset

Frontiers In Immunology

Engineering a juxtamembrane-targeting CAR T-cell against mesothelin: a novel binder resilient to shed antigen for enhanced efficacy against ovarian and pancreatic cancer

Frontiers In Oncology

ERCC6L in human cancers: oncogenic functions, molecular mechanisms, and clinical implications as a prognostic biomarker and therapeutic target